Prevention of cardiovascular events by hypolipidemic therapy evidence-based medicine criteria.
Studies in which hypolipidemic therapy were used for preventing cardiovascular diseases are analyzed on the basis of the number of patients to treat to avoid a clinical event, one of the most accepted evidence-based medicine criteria. The benefit of treatment appears to be related to the risk profile of the population and to the reduction of LDL-Cholesterol concentration but not to the type of therapy. Total mortality is decreased only when statins are used. Special groups of patients (women, aged patients, diabetics) also appear to benefit from the treatment.
Heller
F R
FR
Department of Internal Medicine, C.H. Jolimont-Lobbes, Haine St Paul, Belgium.
D000367:Age Factors; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications; D019317:Evidence-Based Medicine; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D012307:Risk Factors; D018401:Sample Size; D012737:Sex Factors; D015996:Survival Rate
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents